Cingulate Inc (CING) Stock Analysis

Cingulate Inc (CING) is a publicly traded company in the HEALTHCARE sector. It trades at $4.03, carries a market capitalization of $44.61M. This page summarizes the public market data, fundamentals, and frequently asked questions for CING, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cingulate Inc currently has a Bearish sentiment score of -0.16.

About Cingulate Inc

Cingulate Inc. is a clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas, focusing on innovative therapies for neurobiological and central nervous system disorders. The company is advancing a pipeline of proprietary drug candidates aimed at addressing critical unmet needs in the fields of psychiatry and neurology. With its specialized platform designed to optimize therapeutic efficacy, Cingulate is strategically positioned to make a meaningful impact on the future of ...

GNG Research Analysis

GNG Research scores Cingulate Inc (CING) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CING.

Frequently Asked Questions

Does CING pay dividends?

Cingulate Inc (CING) does not currently pay a regular dividend.

What is CING's market cap?

Cingulate Inc (CING) has a market capitalization of $44.61M with a current stock price of $4.03.